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Abstract Multidrug resistance (MDR) is explained by
drug transporters with a drug-handling activity. Despite
much work, MDR remains multifaceted, and several con-
ditions are required to generate drug resistance. The drug
pumping was conceptually described using a kinetic, i.e.,
temporal, approach. The re-emergence of physical biology
has allowed us to take into account new parameters
focusing on the notion of space. This, in turn, has given us
important clues regarding the process whereby drug and
transporter interact. We will demonstrate that the likeli-
hood of drug-transporter meeting (i.e., the affinity) and thus
interaction are also driven by the mechanical interaction
between drug molecular weight (MW) and the membrane
mechanical properties. This should allow us to mechani-
cally control drug delivery.
Keywords Physical biology  Pharmacokinetic 
Membrane  Drug delivery  Multi-drug resistance 
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Position of the problem
Multidrug resistance (MDR) mediated by drug transporters
is a two-sided problem. The first difficulty is to understand
the relationship between the structure and the function of
transporters. The second difficulty is to understand how
and why drugs diffuse toward transporters given the
complex requirement needed for their handling and extru-
sion. This review will focus on the concept of drug diffu-
sion toward transporters.
MDR was initially explained by the overexpression of
drug transporters with a drug-handling activity. It seems
today that MDR is multifaceted and that several conditions
are required to generate drug resistance. Beyond the strict
field of MDR, it is interesting to note that a similar problem
exists in the field of drug bioavailability where similar
transporters impair drug chemicals from reaching their
target. Recently the re-emergence of physical biology
(i.e., trans-disciplinary research fields), also named ‘‘com-
plex fluids or soft-matter (bio)physics,’’ has allowed new
parameters involved in complex biological processes such
as MDR to be taken into account. Interestingly, these
parameters are linked to physics and therefore widen the
conceptual notion of space at the cellular level.
MDR transporter activity, namely drug pumping, was
conceptually described using classical pharmacokinetics,
which uses specific mathematical tools from chemistry that
are focused on kinetics, i.e., time. As chemistry is chiefly a
science of contact, it informs whether, or not, a reaction has
occurred once chemicals meet together, classically given
by Gibbs’ energy. Therefore, unless considering averaged
and approximated bulk diffusion, chemistry does not deal
with the probability of two compounds meeting, or the
reason why a drug and a transporter meet, especially in
spatially heterogeneous systems of biology.
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The science that deals with the notion of ‘‘space’’ is
physics, the role of which is to provide an understanding of
the optimal spatial organization of homogenous and het-
erogeneous systems composed of molecules. Given this
simple thought, it follows that the current challenge in
modeling is to combine the notion of space, recently
developed by complex- or soft-matter (bio)physics, with
the notion of time (kinetics). We will show that this type of
modeling can provide fundamental insights about the effi-
ciencies of time- or space-related biological processes in
MDR: specifically, whether or not the pumping kinetics or
probability of meeting is the most limiting factor in MDR.
Affinity versus specificity in MDR
In very simple terms, biochemistry is the field that studies
the chemistry of biological elements. In the cellular con-
text, this means that biochemistry aims to describe how and
why biological molecules can interact together, based on
structural and molecular aspects. Accordingly, biochemis-
try is a science of contacts. For example Eyring’s theory on
the transition-state/complex activation demonstrates that
the kinetic constant, k, of a reaction is always given by:
k = kBT/hexp(-DG/kBT) where kB, T, h and DG are,
Boltzmann’s constant, the absolute temperature, Planck’s
constant and Gibbs’ energy of the transition state, respec-
tively. This theory forms the basis of any kinetic studies,
and it follows that the limitation of the kinetics of a reac-
tion is given by the occurrence of the transition state,
providing chemicals are already in contact.
Therefore, to interact, chemicals have to have some
ability to react, which is described by Gibbs’ energy and
sometimes catalyzed by enzymes. However, prior to
reacting, chemicals have to come into contact with one
another, which can only be achieved by a specific spatial
organization of systems. Experimentally, it is the term of
‘‘affinity’’ that best describes the notion of interaction.
However, this term deduced experimentally does not dif-
ferentiate between the ability of two molecules to interact
and to react and accordingly, in the notion of ‘‘affinity,’’ the
likelihood (probability) of a reaction is as important as
Gibbs’ energy.
Therefore, although two chemicals may look highly
specific and complementary to one another chemically, the
resulting experimental affinity can be very low if the spatial
organization1 of the system impedes their ability to meet
and thus react together. The converse is also true and has
direct application in drug resistance. Indeed, it may well be
that two chemicals are forced to come together because of
the spatial organization of the system, even if they are not
that specific to one another. In turn, this would likely ele-
vate the experimental affinity measured.
Multi-drug resistance corresponds to a state whereby an
organism is resistant to many drugs that are not necessarily
chemically related. This means that the specificity between
a drug and a transporter, although important, is unlikely to
wholly explain the levels of resistance that result from the
interaction between drugs and transporters. Therefore, it
follows that changes in the spatial organization of MDR
cells have to happen for high affinities between drugs and
transporters to develop and to generate, in due course, high
levels of multi-drug resistance. Again, a reaction resulting
from the collision of two chemicals may not be that effi-
cient2; nonetheless, if one increases the meeting probability
between these two chemicals, or makes sure that they
repeatedly collide to trigger the reaction, then a reaction
can look highly efficient. Based on this, it follows that a
cell will be likely to sustain high levels of resistance if it
has found a way of forcing drug chemicals and transporters
to meet together.
The fundamental role of spatial dimensions
in the ‘‘multi’’ of multi-drug resistance
The ‘‘multi’’ of multi-drug resistance can be explained by
finding a way of forcing drugs and transporters to meet.
Whatever the biological complexity involved in a given
process, the probability of a simple drug and a complex
protein meeting is essentially driven by Brownian (or
equivalently random) diffusion. It follows that the diffusion
itself has to hold a fundamental key to the concept of multi-
drug resistance. Random processes have been studied for
more than a century, and it is now well established that the
mathematical properties of Brownian diffusions are fully
dependent on the dimensions of space. In particular, there
is one theorem, known as Polya’s Theorem, that states that
portions of space are always left unvisited (whatever the
visitation time considered) if the Brownian particle diffuses
in dimensions higher than 2, and that conversely, in
dimensions smaller than or equal to 2, all the space will be
visited possibly more than one time over a long enough
period of time. A ‘‘hand-waving’’ explanation is given in
Fig. 1.
If one associates this later mathematical theorem with
drug resistance, it follows that multi-drug resistance could
be the result of mathematical properties of random
1 Note that ‘‘spatial organization of a system’’ does refer also to
dimensions that we will see are crucial to drug transporter meeting
probability. Indeed, diffusion properties are different in 1, 2 or 3
dimensions.
2 The efficiency defined at the molecular levels is referred as the
number of products created per unit of time.
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diffusions unrelated to the complex biology of drug resis-
tance (i.e., transporters in our case). Indeed, Polya’s The-
orem suggests that a large (and thus relatively static)
membrane transporter would meet a small diffusing drug
embedded in the membrane more than one time. The only
condition for this to happen is that the residence time of the
drug in the membrane has to be long enough. Of course, the
cell membrane has a thickness and is not totally a 2D
object. Nonetheless, if the residence time in the membrane
is long enough, namely that the 2D diffusion occurs over
long distances, the thickness can be neglected; see (Rauch
and Pluen 2007). Note that as the ability of drugs to diffuse
over long distances is fundamentally linked to the physical
interaction between the drug and the membrane, it is the
physics of drug-membrane interaction that would drive, via
Polya’s Theorem, the ‘‘multi’’ of multi-drug resistance.
Of course, Polya’s Theorem and the associated expla-
nation of multi-drug resistance would be better applied to
specific cases where the interaction between a drug and a
transporter is supported by the membrane. As we shall see,
this necessitates specific drug transporters similar to the
well-known Pgp (P-glycoprotein) that expels drugs from
the membrane. Finally, saying that Polya’s Theorem is a
strong argument in favor of drug extrusion from the
membrane does not rule out the possibility that drugs may
also be extruded from the cytosol; nonetheless, this theo-
rem simply suggests that the efficiency would be lower (see
Fig. 1).
Finally, if Polya’s Theorem (including the underlying
physics of drug membrane interaction) has any meaning in
drug resistance to describe drug-transporter affinity, the
notion conveyed by this theorem must already exist in this
field, albeit under a different name. In the field of drug
resistance, an argument similar to Polya’s Theorem has
always been used—say invoked—to represent drug resis-
tance. This argument is the well-known ‘‘vacuum cleaner’’
hypothesis. To fully appreciate this point it is important to
develop the initial steps that have led to the discovery of
drug transporters.
Drug-transporter affinity driven by the physical biology
of the ‘‘vacuum cleaning’’ process
It was in 1973 that Dano Keld suggested that the mecha-
nism of resistance was due to an outward efflux (Dano
1973). This hypothesis clearly took off when a few years
later P-glycoprotein (Pgp) was identified by Juliano and
Ling (1976) as the membrane protein overexpressed in
MDR cancer cells that actively extrude membrane
amphipathic drugs. Since this first discovery, many bio-
logical, biochemical and structural studies have been car-
ried out on this transporter. Pgp consists of a duplicated
structure (tandem structure) composed of around 1,280
amino acids with a MW *170 kDa (Fig. 2). Each half of
the molecule contains a nucleotide-binding domain (NBD)
including six highly hydrophobic transmembrane domains
(TMDs) (Fig. 2) (Borst and Elferink 2002; Shilling et al.
2006). The TMDs are considered to form a cavity through
which hydrophobic drug molecules cross the membrane.
The NH2- and COOH-termini and NBDs are located
intracellularly, and the first extracellular loop is N-gly-
cosylated. Each NBD consists of two Walker A and B
motifs, common to most proteins that bind nucleotides
typical of ATPases (Walker et al. 1982). The two half
molecules are separated by a highly charged ‘linker region’
or C motif, a signature of ABC transporters (Higgins 2007).
Several studies have indicated that a conformational
change in the structure of Pgp upon ATP binding allows
access from the lipid bilayer inner leaflet to the internal
cavity of volume *6,000 A3 that can accommodate up to
two hydrophobic drugs (Aller et al. 2009; Buxbaum 1999;
Romsicki and Sharom 1998; Rosenberg et al. 2001). It has
( ) 2/~~ dd DtRV
dR
Fig. 1 This is certainly not a proof of Polya’s theorem. Nonetheless,
it is a very good exercise to visualize how the spatial dimensions
generate interesting properties regarding Brownian diffusion. Thus,
this is a hand-waving explanation of Polya’s theorem. Let’s consider a
Brownian diffusion in a space for which the dimension is ‘‘d.’’ After a
sufficiently long time, the Brownian particle would have diffused
within a volume V * Rd. The volume of diffusion is necessarily
related to time, and as far as Brownian diffusion is concerned, the
radius of the volume of diffusion is expressed as R * t1/2. Thus, the
volume is related to time by the following relation: V * td/2. As seen
in the figure, as time goes on the particle will visit more and more dots
composing the volume. By dots one means the number of particles
that can be inserted in the defined volume. In actual fact, the number
of dots (N) visited in the volume of diffusion is proportional to time:
N * t. Consequently, the density of dots visited in the volume of
diffusion is: N/V * t1-d/2. As a result, when d [ 2, the ‘‘density of
visitation’’ decreases with time, which means that many sites will be
left unvisited. Conversely, when d B 2, it can be proven that the
density of visitation is always one, which means that all the sites will
be visited at least one time; even so, if for this to happen, we have to
wait long enough. All this formalism is further developed in Rudnick
and Gaspari (2004)
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also been demonstrated that the drug-binding affinity is
more sensitive to ATP binding rather than hydrolysis and
that two ATP molecules need to be bound on each part of
the Pgp to allow its full activation (Kimura et al. 2007;
Martin et al. 2000a, b, 2001; Rosenberg et al. 2001; Sauna
and Ambudkar 2000). Finally, the ability of many drugs to
bind the internal cavity of Pgp is supposed to be linked to
the number of potential binding sites available on the wall
of the internal cavity composed of hydrophobic, aromatic,
polar and charged amino acid residues (Aller et al. 2009).
In addition to the use of crystallography methods and basic
biology, by using reconstituted proteoliposomes as model
systems, it was found that the turnover rate of Pgp ATPase
at maximal drug stimulation is in the range of *1–15ATP/
s (Borgnia et al. 1996; Shapiro and Ling 1995), with a near
stoichiometric substrate transport to ATP hydrolysis
*2ATP/drug [reviewed in (Ambudkar et al. 2006)].
Although Pgp with an extrusion activity from the inner
leaflet is considered as the archetype of drug transporters,
today we also know that other transporters may be involved
in drug resistance as well, be it directly or indirectly, and
that a drug extrusion from the cytosol is not ruled out
(Ayrton and Morgan 2008).
In conclusion, these works on Pgp seemed to have
determined fully the biochemical reason whereby drug
resistance can exist, including the order of magnitude of
the pumping kinetics of Pgp transporters, which in turn
seemed to have solved the problem of MDR. However,
there was a problem not related to the pumping kinetics but
to the fact that Pgps do not cover all the cell membrane of
drug resistant cells. Therefore, the recurring question was
why would Pgps and drugs meet?
It was demonstrated that overexpression of drug trans-
porters, leading to a very high level of resistance, corre-
sponds to *18% of membrane proteins (Borgnia et al.
1996), but that among these *18%, only *70% are
located on the outer plasma membrane (Kim et al. 1997).
Given that on average proteins represent between 20 and
50% of membrane surface area (Koval and Pagano 1991;
Lange et al. 1989; van Meer 1989), it follows that between
*2.5 and *6% of the plasma membrane area contributes
in drug efflux in highly resistant cells. If one excludes drug
diffusion in the membrane, this means that the probability
that a drug incorporates into the membrane in the vicinity
of a Pgp (prior to being extruded) is at most *6%, i.e.,
much less than 1. In addition, it was also found that to be
extruded by a Pgp, the drug has to be in the inner leaflet of
cells (Shapiro et al. 1997; Shapiro and Ling 1997; Sharom
et al. 2005). Thus, for a drug to interact with a transporter,
many non-trivial conditions are required.
These problems lead to the hypothesis initially postu-
lated by Dano Keld, that is, that drug transporters ‘‘vacuum
clean’’ drugs. This hypothesis, besides characterizing the
biochemical extrusion of drugs from the inner leaflet by
transporters, informs indirectly on the ability of two mol-
ecules to meet together (i.e., likelihood of a reaction),
which occurs before any biochemical/contact reactions. As
seen above, this notion of ‘‘vacuum cleaning’’ is very
similar to Polya’s Theorem as long as diffusion and drug-
membrane interaction are considered.
It is interesting to note that if we were in a position of
controlling how drugs and transporters meet together, we
would be in a position of harnessing, albeit indirectly, the
drug pumping as well. Thus, by providing a clear expla-
nation of the elusive ‘‘vacuum cleaner’’ hypothesis, we
should be able to control MDR, at least in theory.
It is important to recall that along with the discovery
of Pgp functionality, results from various laboratories
demonstrated that many other physicochemical cellular
parameters are altered in drug resistant cells. For example,
membrane potential and intracellular pH alteration are
important features in MDR (Roepe 1998; Roepe and
Martiney 1999; Roepe et al. 1993, 1996; Santai et al. 1999),
involved in lowering the influx of charged drugs into cells
and trapping drugs in acidified compartments (Simon 2001;
Simon et al. 1994). This trapping was associated with the
fact that MDR cells re-organize the architecture of their
intracellular organelles, including changes in the kinetics of
membrane recycling, i.e., the ‘‘nonspecific adsorptive
endocytosis,’’ which is known today as fluid-phase endo-
cytosis (Sehested et al. 1987a, b). In addition, and in an
attempt to better understand drug transporters’ function, it
was also found that drugs are extruded from the inner leaflet
of the cell membrane (Shapiro et al. 1997; Shapiro and Ling
1997; Sharom et al. 2005) and that the residence time of
drugs in the cell membrane was an important factor (Eytan
et al. 1997; Regev and Eytan 1997), likely to be tuned with
the pumping kinetics. Given these changes it is interesting
to ask which of these events could potentially mediate the
high affinity expected between drugs and transporters. In
other words, which one of these events could be central to
the ‘‘vacuum cleaning’’ process or, said differently, makes
Polya’s Theorem work by reinforcing the drug-membrane
interaction?
TMD1 TMD2
NBD1 NBD2NH2
COOHC motif
Walker A Walker B
Fig. 2 Sketch of the biochemical structure of a P-glycoprotein
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To finish, we would like to emphasize a particular
seminal study on MDR published 3 years before Dano’s
work, the relevance of which will soon become obvious
when the physical interaction between drug and membrane
has been worked out. It is important to remember that at
that time, i.e., 1970, no membrane drug transporters were
suggested or even thought about. This study published by
Biedler and Riehm (1970) investigated the cross resistance
to actinomycin D using cancer cells (which were later
found to express Pgp). Their conclusion was that the level
of drug resistance could be correlated to the size (MW) of
drugs used, namely that the larger the drug the higher the
resistance, and conversely, the smaller the drug the better
their sensitivity. It is important to emphasize that given the
limited data on MDR, their study did not focus on complex
cellular processes, but on drugs’ physicochemical proper-
ties. We focus on this particular study for two main rea-
sons. The first reason is linked to the fact that a similar
conclusion relating the size (i.e., MW) of a drug and its
ability to traverse bilayer membranes was drawn by the
pharmaceutical industry *30 years later, when it became
interested in drug bioavailability (see below). Indeed,
drug transporters like Pgp are naturally expressed by
certain cells in our body and are involved in the bio-
availability of oral drug chemicals (Chan et al. 2004;
Fromm 2003; Schinkel 1999; Zhang and Benet 2001); it
is known that the MW of drugs is a fundamental factor
affecting their bioavailability that cross-talks with Pgp
functionality (Gleeson 2008; Gombar et al. 2004; Hou
and Xu 2003). The second reason is related to the fact
that the increase in the apparent affinity between drugs
and transporters in MDR can be explained physically by
the mechanical interaction among the drug size (i.e.,
MW), membrane endocytosis (altered in drug resistant
cells) and, of course, drug transporter surface density and
functionality (i.e., drugs’ extrusion from the inner leaflet)
(see the part after next).
Lipinski’s rules and the bioavailability
of drug chemicals
The pharmaceutical industry has adopted a ‘‘megabrand’’
marketing concept that advocates a strong focus on single
products yielding significant returns at peak sales (*$1
billion/annum) (Drews 2003; Oprea 2002). Accordingly,
this vision has emulated the notion of ‘‘blockbusters.’’ It is
therefore understandable that the strategies adopted by
these companies are those that provide information, in
advance of costly clinical trials, about which chemicals are
most likely to become blockbusters. Thus, the properties
that make a chemical a ‘‘likely’’ drug predefine and are
central to the ‘‘blockbuster’’ product. Lipinski’s strategy
answered a real demand in an innovative way. Lipinski and
his collaborators from Pfizer analyzed the physicochemical
properties of marketed oral drugs. Lipinski found that
marketed drugs follow four rules. The first rule is based on
the lipophilic index of drugs (octanol–water partitioning:
logP \ 5), the second rule is based on the drugs’ MW,
which needs to be\500, and the third and fourth rules are
based on the drugs’ state of charge (number of hydrogen-
bond donors, i.e., number of OH ? NH bonds [5; and
number of hydrogen bonds acceptor, i.e., number of O ? N
atoms [10). Together, these rules define the physico-
chemical properties drugs should have to achieve the 90th
percentile of bioavailability (Lipinski et al. 2001). These
rules, which concerned synthetic chemicals, are also found
for natural compounds (Quinn et al. 2008). Given the
potentially huge return from Lipinski’s rules, which pre-
dicts inefficient compounds prior to them reaching the
development stage, this specific route regarding the deter-
mination of drug likeliness properties has been further
developed and refined by others (Proudfoot 2002; Veber
et al. 2002), extending these initial rules to other physi-
cochemical properties that compounds should have (Palm
et al. 1997; Veber et al. 2002). Today, the application of
these guidelines to determine the drug likeliness properties
of potential lead compounds have been largely embraced
by the pharmaceutical industry and, accordingly, Lipinski-
type rules are now an integral part of the decision-making
process in this industry and are now considered drug dis-
covery paradigms. To conclude, we can say that the up-side
of Lipinski’s rules is related to the fact that his study has
focused on the physicochemical properties of drug chem-
icals, bypassing (but not ignoring) complex biology such as
drug transporters. The down-side of Lipinski’s rules,
however, is that (1) only physicochemical margins are
defined (e.g., 0 \ MW \ 500) and (2) rules are not laws,
i.e., there is no explanation provided, albeit the under-
standing of some rules can be inferred to the membrane
(e.g., rule one) or pH changes in the GI tract (e.g., rules
three and four).
If these rules pre-define what chemicals should look like
to cross cell membranes, a similar conclusion is likely to be
valid for chemicals crossing Pgp-expressing MDR cells.
This was indeed shown for the drug MW (see Biedler and
Riehm’s study). The question now is: can we use basic
physics to merge all this different data into one coherent
body of evidence?
Merging Lipinski’s second rule and Biedler
and Riehm’s study
In both the Lipinski (basic drug delivery) and Biedler and
Riehm (drug resistance) studies, the MW of chemicals is
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central. Drugs that are small enough have a MW that is
proportional to their volume, suggesting that drug volume
is a limiting parameter when they cross biomembranes. In
thermodynamic physics, the conjugated parameters of
spatial dimensions, as for example the volume of a drug, is
either the pressure (c.f., the Law of ideal gas: PV = nRT)
or the surface pressure (i.e., mechanical surface tension) if
the membrane is concerned. Given that, to reach their
targets, chemicals have to cross many membrane barriers,
it is very likely that the membrane, and thus the mechanical
surface tension, will be centrally involved in the alteration
of drug transverse movement. Therefore, in the sum of
energies making up the total activation energy required for
a drug to cross cellular membranes, there must exist an
energy term that is a specific function of the drug’s
dimension so that the drug/membrane interaction yields a
significant energy CkBT (kB is Boltzmann’s constant and T
the temperature in Kelvin). Before entering the field of
physics, we will recall in the next part the most important
results (for us) regarding the (bio)physics of the cell
membrane.
A very short history of membrane physics and its role
in endocytosis: from Lipinski’s second rule
to Lipinski’s second law?
Since the mosaic model of the cell membrane, we have
learned a lot from the physical properties of a cell mem-
brane. An essential aspect of the biological matter like the
membrane when considered at the mesoscopic level,
namely between the micro- and macroscopic levels, is that
it is neither totally hard nor totally liquid water. In fact, it is
between both and is thus called soft matter. A property that
is central to these soft objects is that a rather mild change
can trigger an important effect. This is down to the way
entities composing these soft objects self-assemble and
organize themselves to minimize the system energy. The
bilayer membrane, i.e., the cell membrane, is a very good
example (Israelachvili et al. 1980). Based on their amphi-
pathic properties, lipids self-assemble to form bilayer
membranes. In addition, bilayer membranes are soft and
we know that a small change in the lipid asymmetry
between leaflets triggers drastic shape changes (Farge et al.
1990; Farge and Devaux 1992; Seifert et al. 1991). In fact
we now know that the lipid asymmetry between lipid
leaflets of the cellular membrane, mediated by lipid flipp-
ases activity (Seigneuret and Devaux 1984; Seigneuret
et al. 1984), allows the creation of fluid-phase vesicle
(*50 nm radius) (Farge et al. 1999; Rauch and Farge
2000) (Fig. 3a). As said previously, if the drug dimension
and the plasma membrane are considered, the physical
parameter that best fits such an interaction is the leaflets’
surface pressure, r,3 that is related to how packed lipids
are. However, in cells, two types of membrane tension can
be distinguished, the mean surface tension, noted r0, which
corresponds to the sum of leaflet surface tensions, and the
difference in surface tensions, Dr, between the inner and
outer leaflet. Cells have a large reservoir of membrane and
an average membrane tension that is remarkably low,
r0 * 10
-2–10-3 mN/m (Hochmuth et al. 1996; Raucher
and Sheetz 1999), compared to the magnitude of the dif-
ference in surface tensions between leaflets, |Dr| *
0.9 mN/m (Rauch and Farge 2000). Accordingly and given
the magnitude of this parameter, Dr is more likely to be
involved in impairing the transverse movement of chemi-
cals. Dimensionally speaking, the magnitude of the drug
critical cross-section area, ac, can be defined by:
ac ¼ kBT=Dr ð1Þ
In Eq. 1, the minus sign indicates that the membrane is
compressed when drugs traverse it. The difference
in surface tensions, Dr, is associated with the role of
lipid flippases that maintain membrane lipid asymmetry
(Seigneuret and Devaux 1984). In particular, it has been
demonstrated that a particular membrane flippase
actively relocates phosphatidylserine (PS) and phospha-
tidylethanolamine (PE) from the outer into the inner
leaflet of the cell membrane. A consequence of this
inward pumping is a constantly more highly packed inner
leaflet as it contains more phospholipids than the outer
leaflet. It has been demonstrated that this lipid packing
asymmetry between the membrane leaflets leads to fluid-
phase endocytosis (Devaux 2000; Farge 1995; Farge
et al. 1999; Rauch and Farge 2000) (Fig. 3b) and that the
vesicle radius, R, can be expressed as (Rauch and Farge
2000):
R ¼ 8kc=hDr ð2Þ
where kc and h are, respectively, the membrane bending
modulus and membrane thickness. As for drugs small
enough, their MW is proportional to their Van der Waals
volume (expressed in _A3), i.e., MW * V * a3/2, using
Eqs. 1 and 2, a critical MW (MWc) can be determined
(Rauch and Pluen 2007):
MWc ¼ ð4=3
ﬃﬃﬃ
p
p ÞðhRkBT=8kcÞ3=2 ð3Þ
Equation 3 provides a law with regard to the drugs’ size
(or MW) selectivity on their permeation across cellular
membranes (Fig. 3c). Using the numerical values of
physical constants or biological parameters from drug-
sensitive cells, it follows MWc % 240 at 37C (Rauch and
Pluen 2007). Note that this formula would explain why the
3 Note that in the following text, surface pressure or tension will be
used without conceptual difference. In both cases they refer to the
mechanical packing of lipids in membrane leaflets.
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drug size is important for their transverse movement. It is
important to note that if the vesicular radius generated by the
membrane decreases, then the mechanical packing of the
inner leaflet increases which, in turn, decreases MWc. This last
result suggests that cells are able to set up mechanical barriers
to chemicals, simply by changing the lipid asymmetry they
have in the membrane. It is noteworthy that the kinetics of
endocytosis is increased in MDR cells and that, as this
parameter is inversely related to the vesicle radius (Farge et al.
1999; Rauch and Farge 2000), this suggests strongly that this
packing is increased in the MDR state. It is now worth asking
whether one can address the low specificity/high affinity
linked to the ‘‘vacuum cleaner’’ hypothesis, on which Pgp
activity is totally reliant.
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Fig. 3 a Sketch representing the current model linking fluid phase
endocytosis to the membrane phospholipid number asymmetry. In the
left panel, the translocation of dark-headed lipids into the inner leaflet
induces a differential packing of lipids between leaflets leading to
membrane bending and vesiculation. Note that the membrane
recycling that occurs in cells (right panel), i.e., the exocytosis of
vesicles with a size similar to endocytic vesicles, allows the
maintenance of the lipid asymmetry and thus the maintenance of
the differential packing of leaflets at the level of the plasmalemma.
The relationship existing between the lipid number asymmetry and
the vesicle radius is given by Eq. 2. Accordingly, the lipid number
asymmetry has been experimentally deduced from studies on drug-
sensitive cells with a value providing a vesicle radius of about
*35 nm. b Representation of the different energy barriers involved
when a drug traverses the bilayer cellular membrane. Two leaflets
have been represented with an inner leaflet containing more
phospholipids related to the increase in the difference in surface
tensions (upper graph). Energy profiles of lipid packing in both leaflet
(plain curve-middle graph) and hydrophobic core of membrane
(dashed curve-middle graph) are both involved in providing penalty
energies with regard to the transbilayer movement of drugs. As the
inner leaflet is packed, drugs crossing the membrane will be trapped
in this leaflet, which will delay and impair their flow into the cytosol.
The latter effect will be dependent on the size of drugs as bigger drugs
will ‘‘feel more strongly’’ this mechanical barrier. c Plot of Eq. 3,
namely the membrane permeability to drugs related to drug MW and
vesicle radius (i.e., inner leaflet packing). d In the presence of
transporters (blue in the figure), it is expected that the mechanical
activation energy needed for a drug to cross the membrane when cells
are resistant will: increase the residency time of drugs in the
membrane and allow the drug to diffuse laterally in the membrane
(upper panel). In turn this will increase the meeting probability
between a drugs and transporters followed by extrusion. e Plot of
Eq. 4 that predicts the relationship among drug resistance, Pgp
expression level and drug MW. Note that the critical MW is defined
by the vesicle radius (i.e., endocytosis) (see c)
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Explaining the ‘‘vacuum cleaner’’ hypothesis using
Lipinski’s second law?
As stated before, the vacuum cleaner hypothesis charac-
terizes the ability of drugs to meet Pgp. Given that mem-
brane-embedded drug chemicals have a non-negligible
residence time in the membrane (Eytan et al. 1997; Regev
and Eytan 1997), they will diffuse randomly and by chance
may meet a Pgp (c.f., Polya’s Theorem). The condition that
will lead to effective extrusion is that any meeting has to
happen within the inner lealfet (Shapiro et al. 1997;
Shapiro and Ling 1997). The higher mechanical packing of
the inner leaflet is the only parameter that can ensure that
Pgp and drugs effectively meet in the inner leaflet. In this
setting it is possible to deduce the surface density of
transporters needed to trigger drug resistance (Fig. 3d).
Without going into too many details, it is possible to
demonstrate that the critical surface density of transporters,
qPgp
c , covering cells must satisfy (Rauch and Pluen 2007):
qcPgp 
DG
kBT
þ MW
MWc
 2=3
" #
e
MW
MWc
ð Þ2=3 ð4Þ
where DG and MW are the drug dehydration energy and
the drug molecular weight. Note that if the MW of a drug
increases (or equivalently that the vesicle radius decrea-
ses—see Eq. 3), then the surface density of Pgps can
decrease exponentially (Fig. 3e). At constant surface den-
sity of Pgp, this result means that if larger MW drugs were
used, at least larger than the ones used to generate MDR,
then they would, with no doubt, reach transporters and be
extruded. This formula provides a simple explanation of
Biedler and Riehm’s study, based on Lipinski’s second rule
(Eq. 3), namely, the reason why drug size matters in MDR
(Rauch 2009a). Note, however, that Eq. 4 provides the
minimal condition required between the surface density of
drug transporters and the MW of drugs to trigger drugs
extrusion; nonetheless, in practice what is measured is the
IC50 of drug chemicals. Thus, to link this theory to
experiments and test how robust the model is, one needs to
define how IC50s are expected to vary as a function of
parameters discussed above.
IC50s in living systems resistant to drugs
The cellular sensitivity or resistance to drugs is usually
determined using the IC50s method. The IC50 is an indicator
of drug efficiency as it provides the drug concentration
needed to kill 50% of cells in a given population. When
IC50s are compared for an identical drug between sensitive
and resistant cells, the ratio (IC50)MDR/(IC50)non-MDR is
thus related to the amount of drugs able to cross the
membrane per unit of time. In addition, this ratio also
represents the level of resistance. Accordingly, the higher
the IC50, the lower the sensitivity, and thus an inverse
relationship exists between the ability of drugs to cross the
membrane of cells and the IC50s. Given Pgp with a ‘‘drug
handling’’ activity in MDR cells, the kinetic rate of drug
membrane permeation has already been determined (Rauch
and Pluen 2007):
rMDR
rnonMDR
ﬃ e
MW
MWc
ð Þ2=3 DrMDRDrnonMDR1
 
1  qPgp
qcPcp
 !
ð5Þ
rMDR and rnon-MDR are, respectively, the kinetic rates of
drug membrane transverse movement in resistant (sub-
script ‘‘MDR’’) or sensitive (subscript ‘‘non-MDR’’) cells;
DrMDR and Drnon-MDR are, respectively, the difference in
surface tensions in resistant (subscript ‘‘MDR’’) or sensi-
tive (subscript ‘‘non-MDR’’) cells. Note that the differ-
ences in surface tensions have been left in the formula as
they correspond to the physical nature of the packing.
Finally, qPgp and qPcp
c are, respectively, the surface density
of drug transporters and the critical surface density of
transporters. The critical surface density of transporters is
the surface density of transporters needed to trigger full
drug resistance. For example, when qPgp ? qPcp
c , then
rMDR/rnon-MDR ? 0, i.e., the kinetics of membrane, is null.
Note, however, that in a living system resistant to drugs,
there is always the possibility of killing cells by increasing
the extracellular amount of drugs and therefore the ultra-
resistant state, i.e., when qPgp = qPcp
c as defined by Eq. 4,
is never totally reached. Thus, in practice, qPgp \ qPcp
c . It
has to be noted as well that the drug dehydration energy
does not intervene in Eq. 5 as it is cancelled upon
division.
Considering that the IC50s are inversely proportional to
the kinetic rates of the drug’s transverse movement across
the membrane, it follows that:
ln
IC50ð ÞMDR
IC50ð ÞnonMDR
 
¼  ln rMDR
rnonMDR
 
ﬃ MW
MWc
 2=3 DrMDR
DrnonMDR
 1
 
 ln 1  qPgp
qcPgp
 !
ð6Þ
Equation 6 states that drug resistance levels (IC50s)
would result from the interaction between the lipid
packing, the drug size (or MW) and the surface density
of drug transporters. Equation 6 should allow us to test
experimentally the robustness of the model.
Importantly, Eq. 6 contains two major terms, the first is
related to the mechanical interaction between a drug and
membrane, the second to drug transporters. If drug resistance
208 Eur Biophys J (2010) 39:201–211
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occurs without the expression of transporters, then the sec-
ond term must be omitted by posing: qPgp = 0. Note, how-
ever, that if drug transporters are expressed, the first cannot
be omitted as it represents the ‘‘vacuum cleaner’’ effect upon
which transporters activity rely.
Future perspective: challenges ahead for the next
10 years
The points that will be developed now are what remain to
be done. Of course, proving totally Eq. 6 remains central,
but there is now enough evidence that shows that the theory
is sound (see (Rauch 2009a, b; Rauch and Pluen 2007) and
unpublished observation). Therefore, the next paragraphs
will focus on the future challenges.
First challenge ahead: introducing pumping kinetics
What has been exposed so far does not contain any
references to the pumping kinetics of drug transporters.
In fact the model assumes that the pumping kinetics is
instantaneous, namely, that each time a drug meets a Pgp
in the inner leaflet, it is also extruded. Equivalently, this
assumption supposes that the concentration of membrane
embedded drugs is low enough that only one drug mol-
ecule at a time will meet a transporter. Taking into
consideration the drug pumping kinetics will allow for
the fact that a drug can meet a transporter, but that this
transporter is in an occupied state while pumping another
drug. This point is important as not only will it allow us
to consider higher concentrations of drugs, but it will
also allow the design of potentially new therapeutic
strategies based on drug size and ability to move in the
membrane.
Second challenge ahead: introducing pH
Up to now the model has been restricted to the mechanical
properties of the cell membrane. Nonetheless, we know
that recurrent features exist in MDR cells, and cytosolic pH
alkalization is one of them. The next step will be to
determine how a higher pH as observed in MDR can affect
the packing of lipids, thereby influencing the transverse
movement of drugs as a function of their size. As there are
negatively charged lipids in the inner leaflet of the mem-
brane (e.g., phosphatidylserine), it may well be that a
change in pH will affect the way lipids repulse each other,
thereby defining new differences in surface tensions that
are critical for Pgp activity. This will also likely interact
with the drug charge, affecting drugs’ flip-flop rate across
the membrane and their on–off association with the
membrane.
Third challenge ahead: introducing the membrane
potential
What has been exposed so far does not contain any refer-
ences to the charge of drugs. However, in some cases a
change in the membrane potential has been noted that may
facilitate or impede the influx of drugs across the mem-
brane of cells. Note, however, that it is unclear as to
whether the change in membrane potential is direct, e.g.,
mediated by an extra activation/transcription of ion chan-
nels, or indirect and related to the change in pH. This point
will have to be addressed, which will introduce electro-
static interactions between the drug and the membrane
potential within the model, providing a better picture of
MDR.
Fourth challenge ahead: mechanical control of drug
delivery
The new prediction given by the model presented here is
that a physical mechanical interaction takes place when a
drug crosses the cell membrane. In turn this means that if
we could harness this mechanical interaction we should be
in a position of controlling the delivery of drugs, especially
the larger ones. In terms of drug targets, it seems that the
lipid metabolism is one to focus upon. Indeed, it is the cell
that controls how many lipids are synthesized and where
they will be located, i.e., the inner or outer leaflet. By doing
so the cell also controls the mechanical properties of its
membrane, which directly affects the mechanics of the
transverse movement of drugs. There is a real need to find
new biological targets to control the physics of drug
delivery.
Fifth challenge ahead: modeling the complexity of MDR
Multi-drug resistance is not only linked to Pgp expression.
Other transporters exist that are also involved in drug
resistance; MRP1 transports drugs from the cytoplasm and
the present model based on drug-membrane interaction do
not explain the affinity for such transporters (Chang 2007).
In addition, activity of solute carrier proteins (Okabe et al.
2008) is known to affect drug entry into cells, and again the
present model does not describe the role of these carriers.
Therefore, the ultimate and very long-term challenge is to
integrate in a more comprehensive model the true com-
plexity of MDR, which has, on a biophysical level, to
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include lipid charge and specific drug structure/chemical
moieties as well.
Conclusions
We have tried to highlight the fundamental role of
cross-disciplinary research in complex biology. To
understand multi-drug resistance, we have started by a
fundamental mathematical property of diffusive process.
We then have blended this mathematical property to the
physical biology of the cell membrane and the biology
of multi-drug resistance. It is remarkable that a single
cell can create a very complex behavior through rela-
tively simple properties. Finally, we would to emphasize
two points:
• Physical biology must now be an integral part of the
drug discovery process and decision making in the
pharmaceutical industry.
• The physical properties of the plasma membrane
including lipid metabolism are obvious targets if one
has to ameliorate drug bioavailability or circumvent
drug resistance.
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